Featured Exhibitor Spotlight Theater
High-Throughput Serum Proteomics of 1000+ Checkpoint Inhibitor Patients: Insights From nELISA™ Profiling of RADIOHEAD Cohort
Details
April 29 at 12:30 pm – 1:30 pm CDT
Theater C
Presented by Nomic Bio.
Speakers
Presenter: EnJun Yang, PhD
Parker Institute for Cancer Immunotherapy
Research Director
San Francisco, California
Presenter: Nathaniel Robichaud, PhD
Nomic
Partnerships Lead
Montreal, Canada
Event Description
Join us for Lunch!
Proteomics holds great promise for cancer immunotherapy, but widespread adoption has been limited due to high cost, low throughput, and lack of data interoperability across studies. Here, we leverage the nELISA platform in the largest proteomics study to-date on checkpoint inhibitor (CPI) therapy, providing absolute quantification of ~600 circulating proteins in ~3000 samples from the RADIOHEAD cohort. We will describe how the nELISA overcomes barriers to proteomics and enables such large-scale studies identifying clinically actionable mechanisms for CPI resistance and adverse events. We will highlight biomarkers and protein signatures associated with patient outcomes, and discuss their use to better manage immunotherapy patients.